Pharming Group N.V. (PHAR) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Pharming Group Nv.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.855 Hello, everyone, and welcome to this Q1 2025 call. 00:00:03.855 -- 00:00:08.621 So I'm Fabrice Chiraki, I'm the CEO of Farming, and I will be joined on this call today 00:00:08.621 -- 00:00:14.107 by Stephen Torr, our chief commercial officer, Anurag Relin, 00:00:14.107 -- 00:00:19.974 our chief medical officer, and Jeroen Wackermann, our chief financial officer. 00:00:19.974 -- 00:00:22.194 Next slide. 00:00:22.838 -- 00:00:27.263 In this call, we'll be making forward-looking statements that are based upon our current 00:00:27.263 -- 00:00:32.579 insights and plans. As you very well know, this may differ 00:00:32.579 -- 00:00:35.360 from future results. 00:00:35.662 -- 00:00:37.863 Next slide. 00:00:38.245 -- 00:00:42.230 First of all, let me say that I had a great first three months at Farming. 00:00:42.230 -- 00:00:47.316 The passion and the commitment of all employees to serving rare disease patients 00:00:47.316 -- 00:00:53.223 is really palpable throughout the company, whether you are at the production facilities, 00:00:53.223 -- 00:00:56.393 at the headquarter, or with the field. 00:00:56.393 -- 00:01:01.978 And this mindset of going this extra mile is clearly part of the DNA of the company 00:01:01.978 -- 00:01:08.164 and not just a few words on a culture slide as I've seen it actually too often. 00:01:08.164 -- 00:01:09.906 Next slide. 00:01:09.906 -- 00:01:15.191 So everyone is clearly determined to realize the vision that we've set for the company, 00:01:15.191 -- 00:01:21.417 which is to make farming a leading global rare disease company 00:01:21.417 -- 00:01:25.773 with a diverse portfolio and presence in large markets. 00:01:25.773 -- 00:01:31.099 that leverages a proven and efficient clinical development supply chain...